Search Results
Sep 10, 2026, 11:45 ET XtraMaker Enters the Final Days of Its Kickstarter Campaign, With Super Early Bird Pricing Ending Soon
WEPACK Shenzhen: https://youtu.be/W1Wrn7xS5V8?si=CaaSY1ARz1i8tDTqSpain Workshops: https://youtu.be/tdZg2xaY9Ak?si=x7FApgwIkmIpBiFdBehind
More news about: XtraMaker
May 12, 2026, 10:38 ET Yukon Metals Reports 14 g/t Gold in 300-Metre Step-Out Drilling and Optioned Adjacent Sumitomo-Drilled Property
record $55 million for exploration and pre-development in 2026 [9].Western Copper and Gold Corporation (TSX: WRN) (NYSE American: WRN) advances the Casino copper-gold-molybdenum project in west-central Yukon — a project of national significance with 8.5 million
More news about: USA News Group
May 05, 2026, 06:00 ET IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
and License Agreement with GlaxoSmithKline in 2025, IDEAYA plans to discontinue development of IDE275, a small molecule inhibitor of Werner helicase (WRN), and IDE705, a small molecule inhibitor of Pol-Theta helicase (POLQ). The company is currently evaluating strategic options for these assets.Corporate
More news about: IDEAYA Biosciences, Inc.
Feb 12, 2026, 09:38 ET Western Copper and Gold Announces Upsized C$80 Million Bought Deal Financing
VANCOUVER, BC, Feb. 12, 2026 /PRNewswire/ - Western Copper and Gold Corporation. (TSX: WRN) (NYSE American: WRN) (the "Company") is pleased to announce that, due to significant investor demand, it has entered into an amended agreement with Stifel
More news about: Western Copper and Gold Corporation
Feb 11, 2026, 16:33 ET Western Copper and Gold Announces C$50 Million Bought Deal Financing
VANCOUVER, BC, Feb. 11, 2026 /PRNewswire/ - Western Copper and Gold Corporation (TSX: WRN) (NYSE: WRN) (the "Company") is pleased to announce it has entered into an agreement with Stifel Canada, on its own behalf and on behalf of a syndicate
More news about: Western Copper and Gold Corporation
Nov 12, 2025, 17:31 ET WRN Inhibitors Market Enters Growth Phase with Multiple Early-Stage Clinical Programs Underway | DelveInsight
Leading WRN inhibitor companies, such as Nimbus Therapeutics, GlaxoSmithKline, Ideaya Biosciences, Novartis Pharmaceuticals, Vividion Therapeutics, MOMA Therapeutics, Roche, and others, are developing novel WRN inhibitors that can be available in the WRN inhibitors market in the
More news about: DelveInsight Business Research, LLP
Oct 23, 2025, 17:31 ET Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight
HRO761, is a first-in-class WRN helicase inhibitor aimed at treating cancers with dMMR and MSI-H. Tumors with these features accumulate DNA errors and rely heavily on WRN helicase for survival, creating a synthetic lethality opportunity. By selectively inhibiting WRN, HRO761 is intended to eliminate
More news about: DelveInsight Business Research, LLP
Oct 06, 2025, 07:30 ET WESTERN COPPER AND GOLD ANNOUNCES SUBMISSION OF ESE STATEMENT
BC, Oct. 6, 2025 /PRNewswire/ - Western Copper and Gold Corporation ("Western" or the "Company") (TSX: WRN) (NYSE American: WRN) is pleased to announce the submission of its Environmental and Socio-economic Effects Statement ("ESE Statement") for the proposed Casino
More news about: Western Copper and Gold Corporation